Celldex Therapeutics, Inc. (CLDX) 10-Year Financial Performance & Capital Metrics

CLDX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.Show more

Revenue $7M +2.0%
EBITDA -$192M -26.6%
Net Income -$158M -11.6%
EPS (Diluted) -2.45 +16.1%
Gross Margin -2229.77% -38.1%
EBITDA Margin -2733.63% -24.2%
Operating Margin -2778.89% -23.8%
Net Margin -2248.76% -9.4%
ROE -26.84% +28.3%
ROIC -26.14% +21.3%
Debt/Equity 0.01 -13.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 14.5%

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 32.9% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y6.95%

5Y14.46%

3Y14.71%

TTM-73.94%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-45.73%

EPS CAGR

10Y-

5Y-

3Y-

TTM-31.52%

ROCE

10Y Avg-40.67%

5Y Avg-32.66%

3Y Avg-34.44%

Latest-32.86%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	5.48M	6.79M	12.74M	9.54M	3.57M	7.42M	4.65M	2.36M	6.88M	7.02M
Revenue Growth %	0.53%	0.24%	0.88%	-0.25%	-0.63%	1.08%	-0.37%	-0.49%	1.92%	0.02%
Cost of Goods Sold+	4.01M	102.03M	96.17M	66.45M	42.67M	42.53M	53.31M	82.26M	118.01M	163.55M
COGS % of Revenue	0.73%	15.03%	7.55%	6.97%	11.94%	5.73%	11.46%	34.9%	17.15%	23.3%
Gross Profit+	1.47M	-95.24M	-83.43M	-56.91M	-39.1M	-35.12M	-48.66M	-79.9M	-111.13M	-156.53M
Gross Margin %	0.27%	-14.03%	-6.55%	-5.97%	-10.94%	-4.73%	-10.46%	-33.9%	-16.15%	-22.3%
Gross Profit Growth %	1.01%	-65.83%	0.12%	0.32%	0.31%	0.1%	-0.39%	-0.64%	-0.39%	-0.41%
Operating Expenses+	135.02M	139.7M	122.07M	85.94M	15.93M	28.24M	22.58M	35.33M	43.41M	38.55M
OpEx % of Revenue	24.64%	20.59%	9.58%	9.01%	4.46%	3.81%	4.86%	14.99%	6.31%	5.49%
Selling, General & Admin	33.84M	35.98M	25M	19.27M	15.43M	14.46M	20.49M	27.2M	30.91M	38.55M
SG&A % of Revenue	6.17%	5.3%	1.96%	2.02%	4.32%	1.95%	4.41%	11.54%	4.49%	5.49%
Research & Development	100.17M	102.73M	96.17M	66.45M	42.67M	40.53M	56.81M	82.26M	118.01M	163.55M
R&D % of Revenue	18.28%	15.14%	7.55%	6.97%	11.94%	5.46%	12.21%	34.9%	17.15%	23.3%
Other Operating Expenses	1.01M	997K	896K	224K	-42.17M	-26.75M	-54.72M	-74.12M	-105.51M	-163.55M
Operating Income+	-129.54M	-132.92M	-121.53M	-156.44M	-55.03M	-63.35M	-71.24M	-115.23M	-154.54M	-195.08M
Operating Margin %	-23.64%	-19.59%	-9.54%	-16.4%	-15.4%	-8.54%	-15.32%	-48.89%	-22.45%	-27.79%
Operating Income Growth %	-0.06%	-0.03%	0.09%	-0.29%	0.65%	-0.15%	-0.12%	-0.62%	-0.34%	-0.26%
EBITDA+	-128.53M	-128.82M	-116.22M	-152.63M	-50.17M	-59.42M	-68.17M	-112.34M	-151.53M	-191.9M
EBITDA Margin %	-23.45%	-18.98%	-9.12%	-16%	-14.04%	-8.01%	-14.66%	-47.66%	-22.02%	-27.34%
EBITDA Growth %	-0.06%	-0%	0.1%	-0.31%	0.67%	-0.18%	-0.15%	-0.65%	-0.35%	-0.27%
D&A (Non-Cash Add-back)	1.01M	4.09M	5.31M	3.8M	4.86M	3.93M	3.07M	2.9M	3.01M	3.18M
EBIT	-129.54M	-132.92M	-109.33M	-76.4M	-54.52M	-49.57M	-69.15M	-107.1M	-142.04M	-195.08M
Net Interest Income+	0	0	0	0	4.15M	2.41M	505K	2.91M	13.11M	37.22M
Interest Income	0	0	0	0	4.15M	2.41M	505K	2.91M	13.11M	37.22M
Interest Expense	0	0	15.97M	151.09M	0	0	0	0	0	0
Other Income/Expense	2.34M	4.39M	4.21M	4.49M	4.15M	2.41M	959K	2.91M	13.11M	37.22M
Pretax Income+	-127.2M	-128.53M	-117.31M	-151.95M	-50.88M	-60.95M	-70.28M	-112.33M	-141.43M	-157.86M
Pretax Margin %	-23.21%	-18.94%	-9.21%	-15.93%	-14.24%	-8.22%	-15.11%	-47.66%	-20.55%	-22.49%
Income Tax+	0	0	-24.28M	-765K	0	-1.17M	227K	0	0	0
Effective Tax Rate %	1%	1%	0.79%	0.99%	1%	0.98%	1%	1%	1%	1%
Net Income+	-127.2M	-128.53M	-93.03M	-151.18M	-50.88M	-59.78M	-70.51M	-112.33M	-141.43M	-157.86M
Net Margin %	-23.21%	-18.94%	-7.3%	-15.85%	-14.24%	-8.06%	-15.16%	-47.66%	-20.55%	-22.49%
Net Income Growth %	-0.08%	-0.01%	0.28%	-0.63%	0.66%	-0.17%	-0.18%	-0.59%	-0.26%	-0.12%
Net Income (Continuing)	-127.2M	-128.53M	-93.03M	-151.18M	-50.88M	-59.78M	-70.51M	-112.33M	-141.43M	-157.86M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-19.66	-18.99	-10.86	-14.48	-3.47	-2.02	-1.64	-2.40	-2.92	-2.45
EPS Growth %	0.01%	0.03%	0.43%	-0.33%	0.76%	0.42%	0.19%	-0.46%	-0.22%	0.16%
EPS (Basic)	-19.66	-18.99	-10.86	-14.48	-3.47	-2.02	-1.64	-2.40	-2.92	-2.45
Diluted Shares Outstanding	6.47M	6.77M	8.57M	10.44M	14.51M	29.64M	42.87M	46.89M	48.45M	64.39M
Basic Shares Outstanding	6.47M	6.77M	8.57M	10.44M	14.51M	29.64M	42.87M	46.89M	48.45M	64.39M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	294.94M	195.57M	144.76M	99.08M	66.7M	197.84M	410.84M	317.69M	431.69M	747.16M
Cash & Short-Term Investments	289.89M	189.78M	139.43M	94.02M	64.18M	194.42M	408.25M	304.95M	421.7M	725.28M
Cash Only	72.11M	42.46M	40.29M	24.31M	11.23M	43.84M	39.14M	29.43M	34.81M	28.36M
Short-Term Investments	217.78M	147.31M	99.14M	69.71M	52.95M	150.59M	369.11M	275.52M	386.88M	696.92M
Accounts Receivable	970K	1.78M	1.88M	3.16M	1.22M	1.8M	172K	347K	4.53M	700K
Days Sales Outstanding	64.61	95.96	53.85	121	124.12	88.67	13.5	53.74	240.12	36.4
Inventory	-970K	-1.78M	0	-3.16M	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	3.45M	0	1.3M	0	0	0	5.47M	21.18M
Total Non-Current Assets+	42.65M	187.79M	170.87M	56.73M	56.23M	37.99M	33.81M	35.04M	33.93M	45.18M
Property, Plant & Equipment	11.46M	13.19M	10.37M	6.11M	7.5M	7.26M	6.52M	7.75M	6.64M	8.24M
Fixed Asset Turnover	0.48x	0.51x	1.23x	1.56x	0.48x	1.02x	0.71x	0.30x	1.04x	0.85x
Goodwill	8.96M	90.98M	90.98M	0	0	0	0	0	0	0
Intangible Assets	20.79M	81.49M	67.59M	50.62M	48.69M	30.69M	27.19M	27.19M	27.19M	27.19M
Long-Term Investments	0	0	1.8M	1.8M	0	0	0	0	0	0
Other Non-Current Assets	0	0	1.93M	1.93M	41K	41K	104K	104K	107K	9.75M
Total Assets+	337.58M	383.36M	315.62M	155.81M	122.93M	235.84M	444.65M	352.74M	465.63M	792.34M
Asset Turnover	0.02x	0.02x	0.04x	0.06x	0.03x	0.03x	0.01x	0.01x	0.01x	0.01x
Asset Growth %	0.36%	0.14%	-0.18%	-0.51%	-0.21%	0.92%	0.89%	-0.21%	0.32%	0.7%
Total Current Liabilities+	30.24M	35.22M	27.74M	12.6M	11.64M	14.21M	16.53M	18.61M	31.13M	39.5M
Accounts Payable	1.51M	1.74M	1.72M	1.07M	1.17M	1.05M	1.23M	3.34M	3.49M	3.27M
Days Payables Outstanding	137.05	6.22	6.51	5.87	10.04	8.99	8.41	14.82	10.81	7.29
Short-Term Debt	4.42M	0	6.57M	4.53M	1.94M	0	0	0	1.61M	0
Deferred Revenue (Current)	1000K	0	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	18.71M	26.35M	13.11M	2.61M	3.95M	3.37M	1.55M	990K	16.67M	942K
Current Ratio	9.75x	5.55x	5.22x	7.86x	5.73x	13.93x	24.86x	17.07x	13.87x	18.91x
Quick Ratio	9.79x	5.60x	5.22x	8.11x	5.73x	13.93x	24.86x	17.07x	13.87x	18.91x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	17.24M	82.7M	51.52M	19.15M	17.26M	12.28M	8.65M	7.92M	5.33M	5.83M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.71M	2.15M	1.3M	2.59M	928K	2.36M
Deferred Tax Liabilities	4.66M	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	17.24M	82.7M	51.52M	19.15M	15.55M	10.12M	7.35M	5.33M	4.4M	3.47M
Total Liabilities	47.48M	117.93M	79.25M	31.75M	28.91M	26.48M	25.18M	26.53M	36.46M	45.34M
Total Debt+	4.42M	0	6.57M	4.53M	3.66M	3.48M	3.04M	4.03M	2.54M	3.81M
Net Debt	-67.69M	-42.46M	-33.72M	-19.78M	-7.58M	-40.35M	-36.1M	-25.4M	-32.27M	-24.54M
Debt / Equity	0.02x	-	0.03x	0.04x	0.04x	0.02x	0.01x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-7.61x	-1.04x	-	-	-	-	-	-
Total Equity+	290.11M	265.43M	236.37M	124.06M	94.03M	209.36M	419.48M	326.2M	429.17M	747M
Equity Growth %	0.37%	-0.09%	-0.11%	-0.48%	-0.24%	1.23%	1%	-0.22%	0.32%	0.74%
Book Value per Share	44.84	39.21	27.58	11.88	6.48	7.06	9.78	6.96	8.86	11.60
Total Shareholders' Equity	290.11M	265.43M	236.37M	124.06M	94.03M	209.36M	419.48M	326.2M	429.17M	747M
Common Stock	99K	121K	139K	12K	17K	40K	47K	47K	56K	66K
Retained Earnings	-590.96M	-719.49M	-812.52M	-962.44M	-1.01B	-1.07B	-1.14B	-1.26B	-1.4B	-1.56B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	2.31M	2.54M	2.56M	2.58M	2.62M	2.59M	1.89M	1.26M	3.31M	3.31M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-98.89M	-113.04M	-99.93M	-75.23M	-46.41M	-40.4M	-60.91M	-103.73M	-107.29M	-157.78M
Operating CF Margin %	-18.05%	-16.66%	-7.84%	-7.89%	-12.99%	-5.45%	-13.1%	-44.01%	-15.59%	-22.48%
Operating CF Growth %	0.03%	-0.14%	0.12%	0.25%	0.38%	0.13%	-0.51%	-0.7%	-0.03%	-0.47%
Net Income	-127.2M	-128.53M	-93.03M	-151.18M	-50.88M	-59.78M	-70.51M	-112.33M	-141.43M	-157.86M
Depreciation & Amortization	4.01M	4.09M	5.31M	3.8M	4.86M	3.93M	3.07M	1.4M	3.01M	3.18M
Stock-Based Compensation	12.77M	15.32M	12.31M	8.08M	4.55M	3.92M	8.95M	0	23.89M	34.24M
Deferred Taxes	350K	1.01M	-24.28M	-765K	671K	-1.17M	-227K	0	0	0
Other Non-Cash Items	288K	1.64M	11.96M	80.2M	-1.29M	13M	-1.14M	11.09M	-6.22M	-15.73M
Working Capital Changes	10.89M	-6.56M	-12.21M	-15.37M	-4.32M	-299K	-1.05M	-3.9M	13.46M	-21.6M
Change in Receivables	-543K	-814K	-96K	-777K	-777K	-787K	1.57M	-175K	-2.28M	1.93M
Change in Inventory	0	-687K	-3.57M	1.78M	13.89M	0	0	0	0	0
Change in Payables	4.88M	-4.97M	-8.74M	-13.11M	-13.11M	1.64M	3.65M	3.12M	0	0
Cash from Investing+	-50.19M	68.91M	46.47M	29.82M	17.08M	-98.22M	-216.16M	89.94M	-105.78M	-290.13M
Capital Expenditures	-4.88M	-2.75M	-1.79M	-813K	-731K	-1.55M	-1.25M	-1.83M	-1.82M	-1.92M
CapEx % of Revenue	0.89%	0.41%	0.14%	0.09%	0.2%	0.21%	0.27%	0.78%	0.26%	0.27%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-45.31M	-1.8M	-1.79M	342K	0	0	0	0	0	0
Cash from Financing+	193.15M	14.48M	51.29M	29.44M	16.26M	171.23M	272.37M	4.08M	218.46M	441.45M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	4.31M	536K	265K	419K	9K	434K	2.48M	0	2.24M	9.15M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-103.76M	-115.79M	-101.72M	-76.05M	-47.15M	-41.96M	-62.16M	-105.56M	-109.11M	-159.7M
FCF Margin %	-18.93%	-17.06%	-7.98%	-7.97%	-13.2%	-5.66%	-13.36%	-44.79%	-15.85%	-22.75%
FCF Growth %	-0%	-0.12%	0.12%	0.25%	0.38%	0.11%	-0.48%	-0.7%	-0.03%	-0.46%
FCF per Share	-16.04	-17.11	-11.87	-7.28	-3.25	-1.42	-1.45	-2.25	-2.25	-2.48
FCF Conversion (FCF/Net Income)	0.78x	0.88x	1.07x	0.50x	0.91x	0.68x	0.86x	0.92x	0.76x	1.00x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-50.7%	-46.27%	-37.08%	-83.89%	-46.66%	-39.41%	-22.43%	-30.13%	-37.45%	-26.84%
Return on Invested Capital (ROIC)	-47.55%	-44.76%	-42.83%	-76.45%	-43.28%	-37.2%	-19.35%	-25.26%	-33.23%	-26.14%
Gross Margin	26.81%	-1403.48%	-654.7%	-596.68%	-1094.29%	-473.39%	-1046.23%	-3389.94%	-1614.53%	-2229.77%
Net Margin	-2321.11%	-1894.05%	-730.06%	-1585.07%	-1423.96%	-805.88%	-1516.04%	-4765.59%	-2054.76%	-2248.76%
Debt / Equity	0.02x	-	0.03x	0.04x	0.04x	0.02x	0.01x	0.01x	0.01x	0.01x
Interest Coverage	-	-	-7.61x	-1.04x	-	-	-	-	-	-
FCF Conversion	0.78x	0.88x	1.07x	0.50x	0.91x	0.68x	0.86x	0.92x	0.76x	1.00x
Revenue Growth	52.82%	23.83%	87.78%	-25.15%	-62.54%	107.61%	-37.3%	-49.32%	192.02%	1.99%

Revenue by Segment

	2015	2016	2018	2019	2020	2021	2022	2023	2024
Grant	-	-	6.2M	3.1M	5.12M	-	2.3M	6.61M	7.01M
Grant Growth	-	-	-	-49.98%	65.06%	-	-	187.05%	6.09%
Service	-	-	3.34M	473K	2.3M	-	56K	278K	13K
Service Growth	-	-	-	-85.84%	386.47%	-	-	396.43%	-95.32%
Contracts and grants	-	-	-	-	-	4.62M	-	-	-
Contracts and grants Growth	-	-	-	-	-	-	-	-	-
Product development and licensing agreements	-	-	-	-	-	31K	-	-	-
Product development and licensing agreements Growth	-	-	-	-	-	-	-	-	-
Pd1 Immune Checkpoint Inhibitor	1.3M	2.1M	-	-	-	-	-	-	-
Pd1 Immune Checkpoint Inhibitor Growth	-	61.54%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Celldex Therapeutics, Inc. (CLDX) reported $2.6M in revenue for fiscal year 2024. This represents a 72% decrease from $9.3M in 2011.

Celldex Therapeutics, Inc. (CLDX) grew revenue by 2.0% over the past year. Growth has been modest.

Celldex Therapeutics, Inc. (CLDX) reported a net loss of $224.5M for fiscal year 2024.

Dividend & Returns

Celldex Therapeutics, Inc. (CLDX) has a return on equity (ROE) of -26.8%. Negative ROE indicates the company is unprofitable.

Celldex Therapeutics, Inc. (CLDX) had negative free cash flow of $181.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Celldex Therapeutics, Inc. (CLDX) 10-Year Financial Performance & Capital Metrics

CLDX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $7M +2.0%
EBITDA -$192M -26.6%
Net Income -$158M -11.6%
EPS (Diluted) -2.45 +16.1%
Gross Margin -2229.77% -38.1%
EBITDA Margin -2733.63% -24.2%
Operating Margin -2778.89% -23.8%
Net Margin -2248.76% -9.4%
ROE -26.84% +28.3%
ROIC -26.14% +21.3%
Debt/Equity 0.01 -13.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 14.5%

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 32.9% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y6.95%

5Y14.46%

3Y14.71%

TTM-73.94%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-45.73%

EPS CAGR

10Y-

5Y-

3Y-

TTM-31.52%

ROCE

10Y Avg-40.67%

5Y Avg-32.66%

3Y Avg-34.44%

Latest-32.86%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	5.48M	6.79M	12.74M	9.54M	3.57M	7.42M	4.65M	2.36M	6.88M	7.02M
Revenue Growth %	0.53%	0.24%	0.88%	-0.25%	-0.63%	1.08%	-0.37%	-0.49%	1.92%	0.02%
Cost of Goods Sold+	4.01M	102.03M	96.17M	66.45M	42.67M	42.53M	53.31M	82.26M	118.01M	163.55M
COGS % of Revenue	0.73%	15.03%	7.55%	6.97%	11.94%	5.73%	11.46%	34.9%	17.15%	23.3%
Gross Profit+	1.47M	-95.24M	-83.43M	-56.91M	-39.1M	-35.12M	-48.66M	-79.9M	-111.13M	-156.53M
Gross Margin %	0.27%	-14.03%	-6.55%	-5.97%	-10.94%	-4.73%	-10.46%	-33.9%	-16.15%	-22.3%
Gross Profit Growth %	1.01%	-65.83%	0.12%	0.32%	0.31%	0.1%	-0.39%	-0.64%	-0.39%	-0.41%
Operating Expenses+	135.02M	139.7M	122.07M	85.94M	15.93M	28.24M	22.58M	35.33M	43.41M	38.55M
OpEx % of Revenue	24.64%	20.59%	9.58%	9.01%	4.46%	3.81%	4.86%	14.99%	6.31%	5.49%
Selling, General & Admin	33.84M	35.98M	25M	19.27M	15.43M	14.46M	20.49M	27.2M	30.91M	38.55M
SG&A % of Revenue	6.17%	5.3%	1.96%	2.02%	4.32%	1.95%	4.41%	11.54%	4.49%	5.49%
Research & Development	100.17M	102.73M	96.17M	66.45M	42.67M	40.53M	56.81M	82.26M	118.01M	163.55M
R&D % of Revenue	18.28%	15.14%	7.55%	6.97%	11.94%	5.46%	12.21%	34.9%	17.15%	23.3%
Other Operating Expenses	1.01M	997K	896K	224K	-42.17M	-26.75M	-54.72M	-74.12M	-105.51M	-163.55M
Operating Income+	-129.54M	-132.92M	-121.53M	-156.44M	-55.03M	-63.35M	-71.24M	-115.23M	-154.54M	-195.08M
Operating Margin %	-23.64%	-19.59%	-9.54%	-16.4%	-15.4%	-8.54%	-15.32%	-48.89%	-22.45%	-27.79%
Operating Income Growth %	-0.06%	-0.03%	0.09%	-0.29%	0.65%	-0.15%	-0.12%	-0.62%	-0.34%	-0.26%
EBITDA+	-128.53M	-128.82M	-116.22M	-152.63M	-50.17M	-59.42M	-68.17M	-112.34M	-151.53M	-191.9M
EBITDA Margin %	-23.45%	-18.98%	-9.12%	-16%	-14.04%	-8.01%	-14.66%	-47.66%	-22.02%	-27.34%
EBITDA Growth %	-0.06%	-0%	0.1%	-0.31%	0.67%	-0.18%	-0.15%	-0.65%	-0.35%	-0.27%
D&A (Non-Cash Add-back)	1.01M	4.09M	5.31M	3.8M	4.86M	3.93M	3.07M	2.9M	3.01M	3.18M
EBIT	-129.54M	-132.92M	-109.33M	-76.4M	-54.52M	-49.57M	-69.15M	-107.1M	-142.04M	-195.08M
Net Interest Income+	0	0	0	0	4.15M	2.41M	505K	2.91M	13.11M	37.22M
Interest Income	0	0	0	0	4.15M	2.41M	505K	2.91M	13.11M	37.22M
Interest Expense	0	0	15.97M	151.09M	0	0	0	0	0	0
Other Income/Expense	2.34M	4.39M	4.21M	4.49M	4.15M	2.41M	959K	2.91M	13.11M	37.22M
Pretax Income+	-127.2M	-128.53M	-117.31M	-151.95M	-50.88M	-60.95M	-70.28M	-112.33M	-141.43M	-157.86M
Pretax Margin %	-23.21%	-18.94%	-9.21%	-15.93%	-14.24%	-8.22%	-15.11%	-47.66%	-20.55%	-22.49%
Income Tax+	0	0	-24.28M	-765K	0	-1.17M	227K	0	0	0
Effective Tax Rate %	1%	1%	0.79%	0.99%	1%	0.98%	1%	1%	1%	1%
Net Income+	-127.2M	-128.53M	-93.03M	-151.18M	-50.88M	-59.78M	-70.51M	-112.33M	-141.43M	-157.86M
Net Margin %	-23.21%	-18.94%	-7.3%	-15.85%	-14.24%	-8.06%	-15.16%	-47.66%	-20.55%	-22.49%
Net Income Growth %	-0.08%	-0.01%	0.28%	-0.63%	0.66%	-0.17%	-0.18%	-0.59%	-0.26%	-0.12%
Net Income (Continuing)	-127.2M	-128.53M	-93.03M	-151.18M	-50.88M	-59.78M	-70.51M	-112.33M	-141.43M	-157.86M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-19.66	-18.99	-10.86	-14.48	-3.47	-2.02	-1.64	-2.40	-2.92	-2.45
EPS Growth %	0.01%	0.03%	0.43%	-0.33%	0.76%	0.42%	0.19%	-0.46%	-0.22%	0.16%
EPS (Basic)	-19.66	-18.99	-10.86	-14.48	-3.47	-2.02	-1.64	-2.40	-2.92	-2.45
Diluted Shares Outstanding	6.47M	6.77M	8.57M	10.44M	14.51M	29.64M	42.87M	46.89M	48.45M	64.39M
Basic Shares Outstanding	6.47M	6.77M	8.57M	10.44M	14.51M	29.64M	42.87M	46.89M	48.45M	64.39M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	294.94M	195.57M	144.76M	99.08M	66.7M	197.84M	410.84M	317.69M	431.69M	747.16M
Cash & Short-Term Investments	289.89M	189.78M	139.43M	94.02M	64.18M	194.42M	408.25M	304.95M	421.7M	725.28M
Cash Only	72.11M	42.46M	40.29M	24.31M	11.23M	43.84M	39.14M	29.43M	34.81M	28.36M
Short-Term Investments	217.78M	147.31M	99.14M	69.71M	52.95M	150.59M	369.11M	275.52M	386.88M	696.92M
Accounts Receivable	970K	1.78M	1.88M	3.16M	1.22M	1.8M	172K	347K	4.53M	700K
Days Sales Outstanding	64.61	95.96	53.85	121	124.12	88.67	13.5	53.74	240.12	36.4
Inventory	-970K	-1.78M	0	-3.16M	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	3.45M	0	1.3M	0	0	0	5.47M	21.18M
Total Non-Current Assets+	42.65M	187.79M	170.87M	56.73M	56.23M	37.99M	33.81M	35.04M	33.93M	45.18M
Property, Plant & Equipment	11.46M	13.19M	10.37M	6.11M	7.5M	7.26M	6.52M	7.75M	6.64M	8.24M
Fixed Asset Turnover	0.48x	0.51x	1.23x	1.56x	0.48x	1.02x	0.71x	0.30x	1.04x	0.85x
Goodwill	8.96M	90.98M	90.98M	0	0	0	0	0	0	0
Intangible Assets	20.79M	81.49M	67.59M	50.62M	48.69M	30.69M	27.19M	27.19M	27.19M	27.19M
Long-Term Investments	0	0	1.8M	1.8M	0	0	0	0	0	0
Other Non-Current Assets	0	0	1.93M	1.93M	41K	41K	104K	104K	107K	9.75M
Total Assets+	337.58M	383.36M	315.62M	155.81M	122.93M	235.84M	444.65M	352.74M	465.63M	792.34M
Asset Turnover	0.02x	0.02x	0.04x	0.06x	0.03x	0.03x	0.01x	0.01x	0.01x	0.01x
Asset Growth %	0.36%	0.14%	-0.18%	-0.51%	-0.21%	0.92%	0.89%	-0.21%	0.32%	0.7%
Total Current Liabilities+	30.24M	35.22M	27.74M	12.6M	11.64M	14.21M	16.53M	18.61M	31.13M	39.5M
Accounts Payable	1.51M	1.74M	1.72M	1.07M	1.17M	1.05M	1.23M	3.34M	3.49M	3.27M
Days Payables Outstanding	137.05	6.22	6.51	5.87	10.04	8.99	8.41	14.82	10.81	7.29
Short-Term Debt	4.42M	0	6.57M	4.53M	1.94M	0	0	0	1.61M	0
Deferred Revenue (Current)	1000K	0	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	18.71M	26.35M	13.11M	2.61M	3.95M	3.37M	1.55M	990K	16.67M	942K
Current Ratio	9.75x	5.55x	5.22x	7.86x	5.73x	13.93x	24.86x	17.07x	13.87x	18.91x
Quick Ratio	9.79x	5.60x	5.22x	8.11x	5.73x	13.93x	24.86x	17.07x	13.87x	18.91x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	17.24M	82.7M	51.52M	19.15M	17.26M	12.28M	8.65M	7.92M	5.33M	5.83M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.71M	2.15M	1.3M	2.59M	928K	2.36M
Deferred Tax Liabilities	4.66M	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	17.24M	82.7M	51.52M	19.15M	15.55M	10.12M	7.35M	5.33M	4.4M	3.47M
Total Liabilities	47.48M	117.93M	79.25M	31.75M	28.91M	26.48M	25.18M	26.53M	36.46M	45.34M
Total Debt+	4.42M	0	6.57M	4.53M	3.66M	3.48M	3.04M	4.03M	2.54M	3.81M
Net Debt	-67.69M	-42.46M	-33.72M	-19.78M	-7.58M	-40.35M	-36.1M	-25.4M	-32.27M	-24.54M
Debt / Equity	0.02x	-	0.03x	0.04x	0.04x	0.02x	0.01x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-7.61x	-1.04x	-	-	-	-	-	-
Total Equity+	290.11M	265.43M	236.37M	124.06M	94.03M	209.36M	419.48M	326.2M	429.17M	747M
Equity Growth %	0.37%	-0.09%	-0.11%	-0.48%	-0.24%	1.23%	1%	-0.22%	0.32%	0.74%
Book Value per Share	44.84	39.21	27.58	11.88	6.48	7.06	9.78	6.96	8.86	11.60
Total Shareholders' Equity	290.11M	265.43M	236.37M	124.06M	94.03M	209.36M	419.48M	326.2M	429.17M	747M
Common Stock	99K	121K	139K	12K	17K	40K	47K	47K	56K	66K
Retained Earnings	-590.96M	-719.49M	-812.52M	-962.44M	-1.01B	-1.07B	-1.14B	-1.26B	-1.4B	-1.56B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	2.31M	2.54M	2.56M	2.58M	2.62M	2.59M	1.89M	1.26M	3.31M	3.31M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-98.89M	-113.04M	-99.93M	-75.23M	-46.41M	-40.4M	-60.91M	-103.73M	-107.29M	-157.78M
Operating CF Margin %	-18.05%	-16.66%	-7.84%	-7.89%	-12.99%	-5.45%	-13.1%	-44.01%	-15.59%	-22.48%
Operating CF Growth %	0.03%	-0.14%	0.12%	0.25%	0.38%	0.13%	-0.51%	-0.7%	-0.03%	-0.47%
Net Income	-127.2M	-128.53M	-93.03M	-151.18M	-50.88M	-59.78M	-70.51M	-112.33M	-141.43M	-157.86M
Depreciation & Amortization	4.01M	4.09M	5.31M	3.8M	4.86M	3.93M	3.07M	1.4M	3.01M	3.18M
Stock-Based Compensation	12.77M	15.32M	12.31M	8.08M	4.55M	3.92M	8.95M	0	23.89M	34.24M
Deferred Taxes	350K	1.01M	-24.28M	-765K	671K	-1.17M	-227K	0	0	0
Other Non-Cash Items	288K	1.64M	11.96M	80.2M	-1.29M	13M	-1.14M	11.09M	-6.22M	-15.73M
Working Capital Changes	10.89M	-6.56M	-12.21M	-15.37M	-4.32M	-299K	-1.05M	-3.9M	13.46M	-21.6M
Change in Receivables	-543K	-814K	-96K	-777K	-777K	-787K	1.57M	-175K	-2.28M	1.93M
Change in Inventory	0	-687K	-3.57M	1.78M	13.89M	0	0	0	0	0
Change in Payables	4.88M	-4.97M	-8.74M	-13.11M	-13.11M	1.64M	3.65M	3.12M	0	0
Cash from Investing+	-50.19M	68.91M	46.47M	29.82M	17.08M	-98.22M	-216.16M	89.94M	-105.78M	-290.13M
Capital Expenditures	-4.88M	-2.75M	-1.79M	-813K	-731K	-1.55M	-1.25M	-1.83M	-1.82M	-1.92M
CapEx % of Revenue	0.89%	0.41%	0.14%	0.09%	0.2%	0.21%	0.27%	0.78%	0.26%	0.27%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-45.31M	-1.8M	-1.79M	342K	0	0	0	0	0	0
Cash from Financing+	193.15M	14.48M	51.29M	29.44M	16.26M	171.23M	272.37M	4.08M	218.46M	441.45M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	4.31M	536K	265K	419K	9K	434K	2.48M	0	2.24M	9.15M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-103.76M	-115.79M	-101.72M	-76.05M	-47.15M	-41.96M	-62.16M	-105.56M	-109.11M	-159.7M
FCF Margin %	-18.93%	-17.06%	-7.98%	-7.97%	-13.2%	-5.66%	-13.36%	-44.79%	-15.85%	-22.75%
FCF Growth %	-0%	-0.12%	0.12%	0.25%	0.38%	0.11%	-0.48%	-0.7%	-0.03%	-0.46%
FCF per Share	-16.04	-17.11	-11.87	-7.28	-3.25	-1.42	-1.45	-2.25	-2.25	-2.48
FCF Conversion (FCF/Net Income)	0.78x	0.88x	1.07x	0.50x	0.91x	0.68x	0.86x	0.92x	0.76x	1.00x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-50.7%	-46.27%	-37.08%	-83.89%	-46.66%	-39.41%	-22.43%	-30.13%	-37.45%	-26.84%
Return on Invested Capital (ROIC)	-47.55%	-44.76%	-42.83%	-76.45%	-43.28%	-37.2%	-19.35%	-25.26%	-33.23%	-26.14%
Gross Margin	26.81%	-1403.48%	-654.7%	-596.68%	-1094.29%	-473.39%	-1046.23%	-3389.94%	-1614.53%	-2229.77%
Net Margin	-2321.11%	-1894.05%	-730.06%	-1585.07%	-1423.96%	-805.88%	-1516.04%	-4765.59%	-2054.76%	-2248.76%
Debt / Equity	0.02x	-	0.03x	0.04x	0.04x	0.02x	0.01x	0.01x	0.01x	0.01x
Interest Coverage	-	-	-7.61x	-1.04x	-	-	-	-	-	-
FCF Conversion	0.78x	0.88x	1.07x	0.50x	0.91x	0.68x	0.86x	0.92x	0.76x	1.00x
Revenue Growth	52.82%	23.83%	87.78%	-25.15%	-62.54%	107.61%	-37.3%	-49.32%	192.02%	1.99%

Revenue by Segment

	2015	2016	2018	2019	2020	2021	2022	2023	2024
Grant	-	-	6.2M	3.1M	5.12M	-	2.3M	6.61M	7.01M
Grant Growth	-	-	-	-49.98%	65.06%	-	-	187.05%	6.09%
Service	-	-	3.34M	473K	2.3M	-	56K	278K	13K
Service Growth	-	-	-	-85.84%	386.47%	-	-	396.43%	-95.32%
Contracts and grants	-	-	-	-	-	4.62M	-	-	-
Contracts and grants Growth	-	-	-	-	-	-	-	-	-
Product development and licensing agreements	-	-	-	-	-	31K	-	-	-
Product development and licensing agreements Growth	-	-	-	-	-	-	-	-	-
Pd1 Immune Checkpoint Inhibitor	1.3M	2.1M	-	-	-	-	-	-	-
Pd1 Immune Checkpoint Inhibitor Growth	-	61.54%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Celldex Therapeutics, Inc. (CLDX) reported $2.6M in revenue for fiscal year 2024. This represents a 72% decrease from $9.3M in 2011.

Celldex Therapeutics, Inc. (CLDX) grew revenue by 2.0% over the past year. Growth has been modest.

Celldex Therapeutics, Inc. (CLDX) reported a net loss of $224.5M for fiscal year 2024.

Dividend & Returns

Celldex Therapeutics, Inc. (CLDX) has a return on equity (ROE) of -26.8%. Negative ROE indicates the company is unprofitable.

Celldex Therapeutics, Inc. (CLDX) had negative free cash flow of $181.7M in fiscal year 2024, likely due to heavy capital investments.